We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
Cap. Flow
+$275M
Cap. Flow %
2.78%
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$123M
2
NPCE icon
Neuropace
NPCE
+$93.1M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$77.8M
4
JANX icon
Janux Therapeutics
JANX
+$77.2M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M

Top Sells

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$94.6M
2
ABCL icon
AbCellera Biologics
ABCL
+$54.5M
3
ADVM
Adverum Biotechnologies
ADVM
+$54.2M
4
MOH icon
Molina Healthcare
MOH
+$38M
5
PAND
Pandion Therapeutics Inc. Common Stock
PAND
+$31.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Miscellaneous 4.15%
3 Technology 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTIC
101
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$18.8M 0.19%
7,520,600
– –
VRCA icon
102
Verrica Pharmaceuticals
VRCA
$97.7M
$16.7M 0.17%
147,973
– –
LKFT
103
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$15.9M 0.16%
230,905
– –
NAUT icon
104
Nautilus Biotechnolgy
NAUT
$113M
$15.6M 0.16%
1,546,700
+1,497,325
+3,033% +$16.2M
VOR icon
105
Vor Biopharma
VOR
$1.34B
$15.5M 0.16%
41,667
– –
ACHL
106
DELISTED
Achilles Therapeutics
ACHL
$15.5M 0.16%
1,584,845
– –
JNCE
107
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$14.6M 0.15%
2,147,400
+323,800
+18% +$2.69M
QURE icon
108
uniQure
QURE
$3.38B
$14.5M 0.15%
471,174
-497,905
-51% -$16.7M
SYBX
109
DELISTED
Synlogic
SYBX
$14.4M 0.15%
246,444
+111,111
+82% +$6.07M
MIST icon
110
Milestone Pharmaceuticals
MIST
$144M
$14.2M 0.14%
2,583,821
– –
AMGN icon
111
Amgen
AMGN
$234B
$13.9M 0.14%
57,100
-34,400
-38% -$8.46M
RLAY icon
112
Relay Therapeutics
RLAY
$4.11B
$12.8M 0.13%
350,000
– –
ALEC icon
113
Alector
ALEC
$261M
$12.7M 0.13%
611,478
– –
PHGE icon
114
BiomX
PHGE
$3.7M
$12.6M 0.13%
12,176
– –
MAPS
115
DELISTED
WM TECHNOLOGY INC A
MAPS
$12.5M 0.13%
700,400
– –
BLU
116
DELISTED
BELLUS Health Inc.
BLU
$12.3M 0.12%
3,954,800
– –
JBIO
117
Jade Biosciences
JBIO
$1.33B
$12.2M 0.12%
+15,306
New +$12.2M
IMDX
118
Insight Molecular Diagnostics
IMDX
$135M
$12.1M 0.12%
105,000
– –
IPSC icon
119
Century Therapeutics
IPSC
$366M
$11.9M 0.12%
+407,047
New +$10.3M
CNVY
120
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
$11.4M 0.12%
+1,000,000
New +$11.6M
CVRX icon
121
CVRx
CVRX
$78.6M
$11.2M 0.11%
+400,000
New +$11.2M
BSX icon
122
CALL
Boston Scientific
BSX
$67.9B
$10.7M 0.11%
+250,000
New +$10.5M
CVAC
123
PUT
DELISTED
CureVac
CVAC
$10.3M 0.1%
+140,000
New +$14M
SYRS
124
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$10M 0.1%
183,750
– –
CTMX icon
125
CytomX Therapeutics
CTMX
$699M
$9.58M 0.1%
+1,513,168
New +$11.8M
3 4
5
6 7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2021 Portfolio in Review

As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.

  • OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
  • OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
  • OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
  • OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
  • OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
  • OrbiMed opened 24 new positions and closed 24 in Q2 2021.
  • OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.